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Abstract
Background: Controlling the hemodynamic situation of patients who have spinal operation is of
prime importance, and maintaining the heart rate and blood pressure in normal or low- normal levels
in these patients can reduce their bleeding loss. One of the commonly used drugs for this purpose is
remifentanil. Another sedative-hypnotic-analgesic drug, with acceptable effects is dexmedetomidine.
The aim of this study was to compare the effect of dexmedetomidine with remifentanil in spinal op-
eration.
Methods: In a double blind randomized clinical trial, using random sampling method, 60 patients
with the age range of 15-65 years who were candidates for posterior spinal fusion operation were
included. Induction of anesthesia was performed, and both groups received isoflurane 1% during the
surgery. Remifentanil was injected via infusion pump in one group. The patients in the trial group
received dexmedetomidine. As trial outcomes, heart rate and blood pressure were measured before,
after induction and during the operation. Pain score, sedation score and the need to analgesic therapy
were recorded in the recovery room and the ward. Independent sample t-test and chi-square were
used for statistical analysis.
Results: Dexmedetomidine had a significant lowering impact on intraoperative blood pressure and
heart rate compared to remifentanil (p<0.001). The mean of sedation scores after extubation in pa-
tients who received dexmedetomidine was significantly higher than the sedation scores in patients
who received remifentanil (p<0.001). The mean of post-extubation and recovery pain score in pa-
tients taking remifentanil was significantly higher than patients taking dexmedetomidine (p<0.05).
Conclusion: Dexmedetomidine in patients with spinal operation is associated with lower postopera-
tive pain score and intraoperative bleeding. Hemodynamic effects are significantly better in patients
received dexmedetomidine.
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Introduction
Hemodynamic monitoring and maintain-
ing the heartbeat and blood pressure of pa-
tients undergoing spinal surgery is of prime
importance. It leads to better control of
bleeding in the surgical field, particularly in
congested, small and limited areas such as
spine.  Considering the nature of the spinal
fusion surgery as a major surgery with a
possibility of bleeding and the fact that this
surgery is performed on the elderly or
traumatic patients in many circumstances,
the goal is to choose a drug with appropri-
ate hemodynamic effects while providing
good anesthetic depth and short recovery
state. Using a potent and short acting opioid
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such as remifentanil follows this rule. Rem-
ifentanil has been used successfully as an
analgesic-sedative drug in the recent years.
We chose remifentanil because it is an ul-
tra-rapid opiod with safe and convenient
tapering effects. On the other hand, this
drug is as potent as fentanyl. Another seda-
tive-hypnotic-analgesic drug with an ac-
ceptable effect is dexmedetomidine (DEX).
DEX has been known as a highly selective
α2-adrenoreceptor agonist and has been
used as a sedative agent in some operative
and clinical situations (1-3). Some investi-
gators reported that DEX could reduce the
propofol requirement in remifentanil-based
anesthesia for faster postoperative recovery
and more stable intraoperative hemody-
namics (4, 5). However, the exact propofol
sparing impact of DEX during remifentan-
il-based anesthesia has not been well inves-
tigated.
Previous studies have found that DEX
had complex vasodilative and vasoconstric-
tive hemodynamic effects on pre and
postsynaptic α2 -receptors. The effect of
DEX in a lower dose was vasodilation and
its vasoconstriction effects have been pre-
sented in higher doses. Reduction of blood
pressure and heart rate decreased after
long-term DEX usage (6, 7).
Controlling hemodynamic state of pa-
tients who have spinal operation is very
important, and maintaining their heart rate
and blood pressure in normal or low- nor-
mal levels can reduce their bleeding loss.
To increase anesthesia depth and minimize
serious side effects, it is necessary to care-
fully choose and use appropriate drugs dur-
ing the operation. This study was designed
to compare the effect of DEX as an analge-
sic and sedative drug with remifentanil as
an adjuvant drug in anesthesia regiment in
spinal operation.
Methods
Patients
In the present randomized clinical trial
with a parallel design, 60 patients in the age
range of 15-65 years who were candidates
for posterior spinal fusion operation were
included. This study was approved in the
Research Ethical Committee of Iran Uni-
versity of Medical Sciences; written in-
formed consent was obtained from all the
participants. The clinical trial was regis-
tered in the Iranian Clinical Trial Registry
System as IRCT2012081410336N3. A pilot
study of pain reported by patients after spi-
nal fusion surgery revealed that the average
VAS score for pain was 3 with a standard
deviation of 1.4. The sample-size calcula-
tion was based on a maximum allowable
difference of 1 in VAS scores. Inclusion of
30 patients in each group provided a power
of 0.80 when alpha was set at 0.05. Sam-
ples were gathered using random sampling
method and sample size was calculated
based on the following formula:2N = 4(Z∝+Zβ)
Considering alpha= 0.05, beta= 20% and
the calculation power 80%; the sample size
was 60 patients. Eligibility criteria for the
patients included in the trial were: patients
with ASA class I or II, candidates for pos-
terior spinal fusion surgery in maximum 3
levels, surgical time between 2-5 hours,
participation agreement, and without cardi-
ovascular, pulmonary, neurological, neph-
rology and coagulopathy abnormality in
their history and physical examination. All
the operations were performed in Rasool-
Akram hospital complex affiliated to Iran
University of Medical Sciences.
Patients were randomized using block
randomization method and were equally
divided into two trial groups with 30 pa-
tients. They were monitored in the opera-
tion room. The monitoring device was
Massimo (SAADAT Company, Iran) and
we also used electrocardiography, pul-
soxymetry, NIBP and capnograph for these
patients. Therefore, the blood pressure was
monitored in a non-invasive way. Induction
of anesthesia was performed for all the pa-
tients using fentanyl 3 microgram/ kilo-
gram, midazolam 0.1 milligram/kilogram
as premedication and was continued with
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0.2 milligram/kilogram cis-atracurium and
sodium thiopental 5 milligram/kilogram.
This study was double blinded and patients
and their surgeons were both blind to the
intervention and an unknown person of re-
search team prepared encrypted codes sepa-
rately. Both groups received isoflurane 1%
during the surgery as a maintenance regi-
ment. It has been observed that DEX can
decrease the heart rate and induce brady-
cardia in special doses; propofol has this
effect as well. So we chose isoflurane
which does not have this effect and was a
suitable inhalation anesthetic agent for this
study.
As an intervention in one group, remifen-
tanil (Ultiva, Abbott, CA) was injected
firstly using infusion pump with a dose of 1
microgram/kilogram in 15 minutes and
then injected with continuous infusion with
a dose of 0.2 microgram/kilogram/min. In
the other group, patients received DEX
(Precedex, Hospira, USA) firstly via infu-
sion pump with a dose of 1 mi-
crogram/kilogram in 15 minutes continued
followed by an infusion of 0.5 mi-
crogram/kilogram/hour. DEX was prepared
as 4 microgram/milliliters in 0.9% sodium
chloride infusion. For the postoperative
pain control, an infusion pump containing
1000 micrograms of fentanyl was used in
the first day followed by a rate of four mil-
liliters per hour.
As trial outcomes, heart rate and mean ar-
terial blood pressure (MAP) was measured
before and after induction and every 15
minutes during the surgery. In patients with
bradycardia (heart rate<40 bits/minute) and
MAP<50 mmhg, five milligrams of ephed-
rine was injected and recorded; and in non-
responded cases, patients were excluded
from the trial. In patients with increased or
decreased blood pressure, 10% increase or
decrease in isoflurane dosage was used. If
blood pressure or heart rate were still ele-
vated, fentanyl 50 microgram was used. In
hypertensive patients who were non-
responder to isoflourane or fentanyl, nitro-
glycerine infusion was used and they were
then excluded from the study. At the end of
the surgery, all the drugs were discontinued
and patients were extubated and transferred
to the recovery room. In order to provide a
similar condition, 50 microgram of fentanyl
was injected for patients at the end of oper-
ation just after anesthetic drug cessation.
Awakening time after anesthetic drugs ces-
sation, time of discharge from recovery,
surgeon satisfaction score from surgical
field (good, moderate, poor) and bleeding
loss were recorded. Time of discharge from
recovery was estimated according to Al-
drete score.
Pain score, sedation score and the need to
analgesic therapy were recorded in first 30,
60,120 and 360 minutes after entrance to
the recovery room; so patients were evalu-
ated in the ward. In case of analgesic need
(VAS>4) in the recovery and ward, 15 mg
intravenous ketorolac was injected and rec-
orded in the prepared questionnaire.
Statistical analysis
Data were analyzed using SPSS (IBM
statistics) 20.0 software. Data remained
blinded until all data were collected. Quan-
titative variables were presented as mean ±
standard deviation, and qualitative varia-
bles were presented as count and percent-
ages. Independent sample t-test and chi-
square were used for statistical analysis to
compare numerical and categorical data,
respectively between the two groups if they
had a normal distribution. Data without
normal distribution were analyzed through
nonparametric equivalents of the mentioned
tests. Repeated-measures analysis of vari-
ance (ANOVA) was used to review the re-
sults at different time points. All results of
statistical tests lower than 0.05 were as-
sumed as significant.
Results
In this study, baseline variables such as
age, gender, body mass index, having dia-
betes mellitus and hypertension were sig-
nificantly different between the two trial
groups. Female/male ratio in the remifen-
tanil group was 9/21, and it was 12/18
(p=0.401) in the DEX group.
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Four patients in the remifentanil group,
and 2 patients in the DEX group had diabe-
tes (p= 0.890), and 5 patients had hyperten-
sion (p<0.001). Details of comparison be-
tween the two groups were presented in
Table 1.
The mean of blood pressure (p = 0.005)
and heart rate (p<0.001) had significant
changes in patients who received remifen-
tanil and DEX as study intervention com-
pared to the baseline time. In the study pa-
tients, DEX had a significant lowering im-
pact on intraoperative blood pressure and
heart rate compared to remifentanil
(p<0.01).
The mean of sedation scores after extuba-
tion in patients who received DEX was sig-
nificantly higher than sedation scores in
patients who received remifentanil
(p<0.01).
Awakening time in patients of the rem-
ifentanil group was significantly lower than
patients of DEX group (3.11±15.75 vs.
4.89±32.93; p<0.001). There was a signifi-
cant difference between the two groups in
term of need to Fentanyl at 105 minutes
during the operation (p= 0.010). In other
measured times during operation, the need
to fentanyl injection had no significant dif-
ference between the patients of the two
groups. In the first 30 and 60 minutes of
entrance to the recovery room, the need to
analgesic therapy in the remifentanil group
was significantly higher than the DEX
group (p<0.05); but there were no signifi-
cant differences between the two groups in
the other measured times in recovery. Dis-
charge time in patients of the remifentanil
group was significantly lower than the pa-
tients in the DEX group (3.39±33.25 vs.
5.36±48.54; p<0.001). The mean of post-
extubation pain score of patients in the
remifentanil group was significantly higher
than the patients in the DEX group (0.4±2.1
vs. 0.3±1.8; p=0.03). The mean pain scores
one and two hours after entering the recov-
ery ward in was significantly higher in the
remifentanil group comparing the DEX
group (p<0.001). Six hours after extuba-
tion, the mean pain score was not signifi-
cantly different between the two groups
(0.4±2.9 vs. 0.8±2.7; p=0.2). Surgeons
were more satisfied with the observed out-
comes in patients of the DEX group com-
pared to the patients of the remifentanil
group (100% vs. 78.6%; p=0.01). Bleeding
loss during operation was significantly
lower in patients in the DEX group.
(p<0.05)
Table 1. Descriptive statistics of demographic variables
Parameters
Remifentanil (n=30)
(Mean±SD)
Deoxmedtomidine(n=30)
(Mean±SD)
p
Age 54±7.65 55.57±8.95 0.480
BMI (Mean±SD) 25.88±2.37 26.50±2.86 0.420
Awakening time (min) 15.7±3.10 32.9±4.90 <0.001
Discharge time from recovery (min) 33.3±3.80 48.5±5.40 <0.001
Graph1- Time series of Mean Arterial Pressure (MAP)
and Pulse rate (PR) among study participants
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Discussion
Although in this present study the mean
blood pressure (BP) and heart rate (HR)
revealed significant difference in both
drugs, DEX had a significant lowering im-
pact on intra-operative BP and HR com-
pared to remifentanil. Sedation after extu-
bation was significantly higher in patients
who received DEX compared to patients
who received remifentanil. In addition, in
the DEX group lower need to analgesic was
observed in some intra-operative times and
more specifically in postoperative period.
Some previous studies found relatively
similar trial findings and reported that DEX
can make 30-50% reduction in the propofol
requirement in concomitant use of DEX in
adolescent patients and healthy volunteers
(1, 2). It seems that the sedative impact of
DEX in patients is mediated by locus ce-
ruleus in the brain stem. In this region,
DEX decreases sympathetic and increases
parasympathetic outflow (8, 9).
Laryngoscope insertion and endotracheal
intubation can induce the sympathetic
nervous system and cause severe tachycar-
dia, hypertension or arrhythmia (10). Sev-
eral studies had been performed on the re-
duction of these cardiovascular responses.
DEX is  a very effective alpha-2 agonist
and has more impact on stabilizing cardio-
vascular system after intubation and reduc-
es the  need to analgesic and sedative drugs
preoperatively (11). Some investigators
such as Segal et al. reported  a decrease in
requirement for halothane, and Aho et al.
Table 2. Descriptive statistics of blood pressure and heart rate between two trial groups
Time Remifentanil Dexmedtomidine
Before induction MAP 100.96 ± 16.57 80.18 ± 8.44
HR 77.96 ± 10.91 80.18 ± 8.44
After intubation MAP 112.89 ± 22.23 98.32 ± 7.05
HR 96.96 ± 9.03 98.32 ± 7.05
15  minutes after operation
begin
MAP 95.32 ± 15.54 84.29 ± 8.58
HR 84.25 ± 5.76 84.29 ± 8.57
30  minutes after operation
begin
MAP 89.64 ± 14.96 77.29 ± 6.15
HR 79.25 ± 4.39 72.29 ± 6.15
45  minutes after operation
begin
MAP 88.04 ± 13.08 72.68 ± 7.01
HR 77.14 ± 4.12 68.57 ± 10.08
60  minutes after operation
begin
MAP 90.0 ± 22.60 68.57 ± 10.08
HR 75.43 ± 4.07 68.58 ± 7.01
75  minutes after operation
begin
MAP 83.50 ± 8.88 66.64 ± 10.08
HR 73.07 ± 13.76 66.64 ± 10.01
90  minutes after operation
begin
MAP 82.50 ± 9.08 66 ± 10.11
HR 75.29 ± 5.69 66 ± 10.10
105  minutes after operation
begin
MAP 83.21 ± 10.29 65.64 ± 10.41
HR 76.14 ± 7.46 65.64 ± 10.40
120  minutes after operation
begin
MAP 83.57 ± 7.56 65.18 ± 9.01
HR 76.0 ± 6.84 65.18 ± 9.02
150  minutes after operation
begin
MAP 83.61 ± 5.67 64.64 ± 9.11
HR 77.64 ± 7.95 64.64 ± 9.11
180  minutes after operation
begin
MAP 81.89 ± 6.02 65.21 ± 9.05
HR 77.43 ± 7.02 65.21 ± 9.05
210  minutes after operation
begin
MAP 82.14 ± 6.45 66.14 ± 10.12
HR 76.61 ± 6.43 66.14 ± 10.12
240  minutes after operation
begin
MAP 83.52 ± 5.69 67.57 ± 10.03
HR 77.63 ± 6.03 67.57 ± 10.03
p <0.001 <0.001
Table 3. Mean of sedation scores between patients of both trial groups
Study group Sedation score Remifentanil
(Mean±sd)
Deoxythymidine
(Mean±sd)
p
After extubation 2.9±0.36 3.11±0.32 < 0.001
30 minutes later 1.0±0.01 2.96±0.19 < 0.001
60 minutes later 1.18±0.39 2.61±0.57 < 0.001
120 minutes later 2.0±0.01 1.96±0.19 < 0.001
360 minutes later 2.0±0.01 2±0.01 < 0.001
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reported a decrease in a requirement for
isoflurane up to 90% (12, 13). Moreover, in
one study, the dosage of thiopental sodium
was significantly decreased after using
DEX in anesthesia (14). DEX can decline
the serum level of catecholamine and nore-
pinephrine against some of the stressful
stimuli such as intubation (15).
Some other studies reported that DEX
have complex of vasodilation and vasocon-
striction impacts, by activating pre-synaptic
α2-receptors on sympathetic and post-
synaptic α2 -receptors of the central nerv-
ous system medicates vasodilation, and by
effects on post-synaptic α2 -receptors on
vascular smooth muscle cells can mediate
vasoconstriction impacts (16-18). Some
previous studies reported a biphasic and
dose-dependent impact for DEX on the
blood pressure and heart rate of patients
(17, 18). On the other hand, DEX increases
BP in the short-term usage and decreases
BP in patients in the long time usage. DEX
in low dosage (plasma concentrations, 0.7-
1.2 ng/ml) causes reduction in the release
of norepinephrine release and an inhibition
of sympathetic neurotransmission by acti-
vating α2A receptors (6, 8, 19).  The high
dosage of DEX (i.e., plasma concentra-
tions, >1.9 ng/ml) produces α2B receptor-
mediated vasoconstriction (6, 8). Most pre-
vious studies confirmed cardiovascular de-
pressive effects of DEX and reported an
increase in the incidence of hypotension
and bradycardia (7, 14, 19). The propofol-
sparing effect of DEX may be beneficial
for the reduction of the propofol dosage
and may avoid the adverse effects such as
myocardial depression, metabolic acidosis,
impaired platelet aggregation and extended
recovery caused by prolonged and large-
dose administration of propofol (20-24).
This study had some limitations that
should be considered for the future studies
in this filed. Firstly, our study was per-
formed in one hospital and with patients
with one type of operation. Conducting
multicenter studies with patients of differ-
ent operation types is recommended. Sec-
ondly, some of the disease characters in
spinal regions might have effects on their
hemodynamic changes. For the future stud-
ies, it is recommended to match the study
variables and randomly select the partici-
pants while excluding patients with previ-
ous history of hemodynamic changes.
Conclusion
Dexmedetomidine in patients with spinal
operation is associated with lower postop-
erative pain score and intraoperative bleed-
ing; Hemodynamic effects are also signifi-
cantly better in the DEX group.
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